

12/11/01
JC951 U.S. PTO

Please type a plus sign (+) inside this box



PTO/SB/05 (11-00)

Approved for use through 10/31/2002 OMB 0651-0032 U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications
under 37 CFR 1.53(b))

Attorney Docket No.	690068.405C3
First Inventor	Nicholas Ling
Title	METHODS FOR TREATMENT OF MULTIPLE SCLEROSIS USING PEPTIDE ANALOGUES OF HUMAN MYELIN BASIC PROTEIN
Express Mail Label No.	EV020612829US

1. Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original and a duplicate for fee processing)	7. CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)
2. <input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.	8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
3. <input checked="" type="checkbox"/> Specification [Total Pages <u>30</u>] (preferred arrangement set forth below) - Descriptive title of the Invention - Cross Reference to Related Applications - Statement Regarding Fed sponsored R & D - Reference to sequence listing, a table, or a computer program listing appendix - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings (if filed) - Detailed Description - Claim(s) - Abstract of the Disclosure	9. Computer Readable Form (CRF) 10. Specification Sequence Listing on: i. CD-ROM or CD-R (2 copies); or ii. paper 11. Statements verifying identity of above copies
4. <input checked="" type="checkbox"/> Drawing(s) (35 U.S.C. 113) [Total Sheets <u>4</u>] 5. Oath or Declaration [Total Sheets <u>3</u>] a. Newly executed (original or copy) b. <input checked="" type="checkbox"/> Copy from a prior application (37 CFR 1.63 (d)) (for a continuation/divisional with Box 18 completed) i. <u>DELETION OF INVENTOR(S)</u> Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b)	12. English Translation Document (if applicable) 13. Information Disclosure Statement (IDS)/PTO-1449 14. X Preliminary Amendment 15. X Return Receipt Postcard (MPEP 503) Should be specifically itemized 16. X Certified Copy of Priority Document(s) (if foreign priority is claimed) 17. X English Translation Document (if applicable) 18. Request and Certification under 35 U.S.C. 122(b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent. 19. Other: _____
6. <input checked="" type="checkbox"/> Application Data Sheet. See 37 CFR 1.76	

18. If a CONTINUING APPLICATION OR APPLICATION CLAIMING FOREIGN PRIORITY, check appropriate box, and supply the
requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76
 Continuation Divisional Continuation-in-part (CIP) Claims priority from U.S. application
No. 08/342,408, filed 11/18/94

Prior application information Examiner Michael Borin, Ph.D.

Group Art Unit 1631

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or
declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or
divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a
portion has been inadvertently omitted from the submitted application parts.

19. CORRESPONDENCE ADDRESS

Correspondence address below		or:	X Customer Number or Bar Code Label
Firm Name			
Address			
City, State, Zip	00500		

Signature

12/11/01

12/11/01

By signing this Statement, this firm is certifying that it has a complete, true, and accurate copy of the above application on file with this Office, and further certifying that the information contained in the above application is true and accurate to the best of the knowledge and belief of the undersigned. I further declare that I am the attorney of record for the above-named inventor(s) and that I am duly authorized to sign this Statement on his/her behalf.

12/11/01
10/015540

12/11/01
10/015540